JP2010538066A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010538066A5 JP2010538066A5 JP2010524023A JP2010524023A JP2010538066A5 JP 2010538066 A5 JP2010538066 A5 JP 2010538066A5 JP 2010524023 A JP2010524023 A JP 2010524023A JP 2010524023 A JP2010524023 A JP 2010524023A JP 2010538066 A5 JP2010538066 A5 JP 2010538066A5
- Authority
- JP
- Japan
- Prior art keywords
- azithromycin
- pharmaceutical preparation
- less
- amount
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229960004099 azithromycin Drugs 0.000 claims description 34
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 34
- 206010000496 acne Diseases 0.000 claims description 17
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 16
- 208000017520 skin disease Diseases 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000036470 plasma concentration Effects 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 24
- 239000002775 capsule Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000007787 solid Substances 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000007909 solid dosage form Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000007892 solid unit dosage form Substances 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 description 7
- 229960002180 tetracycline Drugs 0.000 description 7
- 235000019364 tetracycline Nutrition 0.000 description 7
- 229930101283 tetracycline Natural products 0.000 description 7
- 150000003522 tetracyclines Chemical class 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- -1 tetracycline compounds Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96750407P | 2007-09-05 | 2007-09-05 | |
| PCT/US2008/010355 WO2009032268A1 (en) | 2007-09-05 | 2008-09-04 | Azithromycin for treatment of skin disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010538066A JP2010538066A (ja) | 2010-12-09 |
| JP2010538066A5 true JP2010538066A5 (enExample) | 2011-10-13 |
Family
ID=40407900
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010523991A Revoked JP2010538062A (ja) | 2007-09-05 | 2008-07-30 | 徐放性アジスロマイシン固形製剤 |
| JP2010524023A Withdrawn JP2010538066A (ja) | 2007-09-05 | 2008-09-04 | 皮膚疾患治療用アジスロマイシン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010523991A Revoked JP2010538062A (ja) | 2007-09-05 | 2008-07-30 | 徐放性アジスロマイシン固形製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8124123B2 (enExample) |
| EP (2) | EP2197420A4 (enExample) |
| JP (2) | JP2010538062A (enExample) |
| KR (2) | KR20100063088A (enExample) |
| CN (2) | CN101861138A (enExample) |
| AR (1) | AR068368A1 (enExample) |
| AU (2) | AU2008295579A1 (enExample) |
| BR (1) | BRPI0816268A2 (enExample) |
| CA (2) | CA2697496A1 (enExample) |
| RU (2) | RU2010109358A (enExample) |
| WO (2) | WO2009032037A1 (enExample) |
| ZA (2) | ZA201001649B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2218448T1 (sl) | 2002-12-13 | 2016-01-29 | Durect Corporation | Sistem za oralno dajanje zdravila, ki obsega tekoči nosilec materialov z visoko viskoznostjo |
| CA2706658A1 (en) | 2007-12-06 | 2009-06-18 | Durect Corporation | Methods useful for the treatment of pain, arthritic conditions or inflammation associated with a chronic condition |
| US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
| AU2014233453A1 (en) | 2013-03-15 | 2015-10-01 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
| CN120617214A (zh) | 2016-07-06 | 2025-09-12 | 度瑞公司 | 具有药物组成物、屏障层及药物层的口服剂型 |
| CA3176428A1 (en) * | 2016-10-06 | 2018-04-12 | Orbus Therapeutics, Inc. | Formulations for administration of eflornithine |
| CN109875970B (zh) * | 2019-01-08 | 2021-08-06 | 石家庄四药有限公司 | 阿奇霉素固体制剂及其制备方法 |
| CN113116859B (zh) * | 2021-04-12 | 2022-08-30 | 海南普利制药股份有限公司 | 阿奇霉素丸芯包衣制剂 |
| WO2023283427A2 (en) * | 2021-07-09 | 2023-01-12 | Verdure Biotech, Inc. | Enteric and delayed release formulations of locally bioavailable drugs (lbd) targeting the colon |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| US5605889A (en) * | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| JP2977907B2 (ja) * | 1994-05-06 | 1999-11-15 | ファイザー・インコーポレーテッド | アジスロマイシンの放出調節された剤形 |
| US5543417A (en) * | 1994-10-21 | 1996-08-06 | Merck & Co., Inc. | Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents |
| CA2275604A1 (en) * | 1997-01-03 | 1998-07-09 | Kenneth Iain Cumming | Sustained release cisapride mini-tablet formulation |
| US6368628B1 (en) * | 2000-05-26 | 2002-04-09 | Pharma Pass Llc | Sustained release pharmaceutical composition free of food effect |
| US7670627B2 (en) * | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
| BRPI0413927B8 (pt) * | 2003-08-29 | 2021-05-25 | Lifecycle Pharma As | composição farmacêutica compreendendo tacrolimus, forma de dosagem, uso da composição, e, método para a preparação da composição |
| US20050239723A1 (en) * | 2004-04-27 | 2005-10-27 | Amin Avinash N | Compositions and methods useful for treatment of acne |
| CA2591923A1 (en) | 2004-12-21 | 2006-06-29 | Pfizer Products Inc. | Enteric coated azithromycin multiparticulates |
| US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
| US20070264334A1 (en) * | 2005-04-08 | 2007-11-15 | Ju Tzuchi R | Pharmaceutical formulations |
| BRPI0617693A2 (pt) * | 2005-11-09 | 2011-08-02 | Dow Pharmaceutical Sciences | azitromicina para o tratamento de rosácea granulomatosa |
| US7704959B2 (en) * | 2006-10-03 | 2010-04-27 | Dow Pharmaceutical Sciences | Azithromycin for the treatment of nodular acne |
-
2007
- 2007-12-17 US US12/002,417 patent/US8124123B2/en not_active Expired - Fee Related
-
2008
- 2008-07-30 WO PCT/US2008/009169 patent/WO2009032037A1/en not_active Ceased
- 2008-07-30 CA CA2697496A patent/CA2697496A1/en not_active Abandoned
- 2008-07-30 AU AU2008295579A patent/AU2008295579A1/en not_active Abandoned
- 2008-07-30 BR BRPI0816268A patent/BRPI0816268A2/pt not_active IP Right Cessation
- 2008-07-30 RU RU2010109358/15A patent/RU2010109358A/ru unknown
- 2008-07-30 CN CN200880105792A patent/CN101861138A/zh active Pending
- 2008-07-30 JP JP2010523991A patent/JP2010538062A/ja not_active Revoked
- 2008-07-30 EP EP08780336A patent/EP2197420A4/en not_active Withdrawn
- 2008-07-30 KR KR1020107006490A patent/KR20100063088A/ko not_active Withdrawn
- 2008-09-04 EP EP08829925A patent/EP2197453A4/en not_active Withdrawn
- 2008-09-04 CA CA2697537A patent/CA2697537A1/en not_active Abandoned
- 2008-09-04 AU AU2008296903A patent/AU2008296903A1/en not_active Abandoned
- 2008-09-04 KR KR1020107006491A patent/KR20100054842A/ko not_active Withdrawn
- 2008-09-04 AR ARP080103847A patent/AR068368A1/es not_active Application Discontinuation
- 2008-09-04 RU RU2010109359/15A patent/RU2010109359A/ru not_active Application Discontinuation
- 2008-09-04 WO PCT/US2008/010355 patent/WO2009032268A1/en not_active Ceased
- 2008-09-04 CN CN200880105803A patent/CN101835475A/zh active Pending
- 2008-09-04 JP JP2010524023A patent/JP2010538066A/ja not_active Withdrawn
-
2010
- 2010-03-08 ZA ZA2010/01649A patent/ZA201001649B/en unknown
- 2010-03-10 ZA ZA2010/01705A patent/ZA201001705B/en unknown
-
2012
- 2012-01-25 US US13/357,722 patent/US20120121702A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010538066A5 (enExample) | ||
| RU2743643C2 (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| AU2012321110B2 (en) | Combination treatment | |
| ES2988617T3 (es) | Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales | |
| JP2018507243A5 (enExample) | ||
| KR20100052556A (ko) | 난청 치료 및 예방을 위한 1-아미노-알킬시클로헥산 유도체 | |
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
| JP2021509395A5 (enExample) | ||
| CA2570474A1 (en) | A combination composition comprising paracetamol and ibuprofen | |
| EP3193907A1 (en) | Method of treating prader-willi syndrome | |
| TWI441639B (zh) | 用於治療卵巢癌之包含紫杉醇之組合 | |
| JP2016505050A5 (enExample) | ||
| IL272834B1 (en) | Compositions of amantadine, their preparation, and methods of use | |
| TWI341728B (en) | Combinations comprising epothilones and anti-metabolites | |
| JP2019513706A5 (enExample) | ||
| CA3044091A1 (en) | Tofacitinib and baclofen compositions and applications | |
| ES2734280T3 (es) | Composición farmacéutica para su uso en el tratamiento de infecciones de transmisión sexual | |
| TW202038934A (zh) | 用於治療癌症之口服投予多西紫杉醇（ｄｏｃｅｔａｘｅｌ）和Ｐ－ｇｐ抑制劑的醫療組合 | |
| KR20200014880A (ko) | 테세탁셀 및 카페시타빈에 대한 투약 일정 | |
| TWI845578B (zh) | 用於治療癌症之口服愛萊諾迪肯（ｉｒｉｎｏｔｅｃａｎ）與Ｐ－ｇｐ抑制劑的醫療組合 | |
| KR20140056179A (ko) | 치과 감염 치료를 위한 세크니다졸의 사용 | |
| KR20120104574A (ko) | 티보자닙과 템시롤리무스의 조합물 | |
| JP2009507850A5 (enExample) | ||
| RU2008108216A (ru) | Фармацевтические дозированные формы и составы, содержащие лекозотан | |
| HK40123938A (zh) | 用於治疗X-ALD的甲状腺β激动剂给药方案 |